Selected research
Market Outlook & Growth Opportunities
Global Rare Disease Therapeutic Market Outlook and Growth Opportunities 2026
Market perspective
The global Rare Disease Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Rare Disease Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Rare Disease Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rare Disease Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Rare Disease Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Rare Disease Therapeutic market include Bristol-Myers Squibb, Bayer, AstraZeneca, Pfizer, Novo Nordisk A/S, Sanofi SA, AbbVie, F Hoffmann-La Roche and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Rare Disease Therapeutic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Rare Disease Therapeutic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Rare Disease Therapeutic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Rare Disease Therapeutic market.
Rare Disease Therapeutic Segment by Company
Bristol-Myers Squibb
Bayer
AstraZeneca
Pfizer
Novo Nordisk A/S
Sanofi SA
AbbVie
F Hoffmann-La Roche
Amgen
Eisai
Novartis AG
Rare Disease Therapeutic Segment by Type
Biologics
Biosimilar
Small Molecules
Rare Disease Therapeutic Segment by Application
Hematologic Disease
Cancer
Infectious Disease
Cardiovascular Disease
Metabolic Disease
Endocrine Disease
Musculoskeletal Disease
Others
Rare Disease Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Rare Disease Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Rare Disease Therapeutic key companies, revenue, market share, and recent developments.
3. To split the Rare Disease Therapeutic breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Rare Disease Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Rare Disease Therapeutic significant trends, drivers, influence factors in global and regions.
6. To analyze Rare Disease Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rare Disease Therapeutic industry.
Chapter 3: Detailed analysis of Rare Disease Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Rare Disease Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Rare Disease Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Rare Disease Therapeutic Industry Trends
Table 2. Rare Disease Therapeutic Industry Drivers
Table 3. Rare Disease Therapeutic Industry Opportunities and Challenges
Table 4. Rare Disease Therapeutic Industry Restraints
Table 5. Global Rare Disease Therapeutic Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Rare Disease Therapeutic Revenue Share by Company (2021-2026)
Table 7. Global Rare Disease Therapeutic Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Rare Disease Therapeutic Key Company Manufacturing Base & Headquarters
Table 9. Global Rare Disease Therapeutic Company, Product Type & Application
Table 10. Global Rare Disease Therapeutic Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Rare Disease Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Biologics
Table 15. Significant Companies of Biosimilar
Table 16. Significant Companies of Small Molecules
Table 17. Global Rare Disease Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 18. Global Rare Disease Therapeutic Sales Value by Type (2021-2026) & (US$ Million)
Table 19. Global Rare Disease Therapeutic Sales Value by Type (2027-2032) & (US$ Million)
Table 20. Global Rare Disease Therapeutic Sales Value Share by Type (2021-2026)
Table 21. Global Rare Disease Therapeutic Sales Value Share by Type (2027-2032)
Table 22. Significant Companies of Hematologic Disease
Table 23. Significant Companies of Cancer
Table 24. Significant Companies of Infectious Disease
Table 25. Significant Companies of Cardiovascular Disease
Table 26. Significant Companies of Metabolic Disease
Table 27. Significant Companies of Endocrine Disease
Table 28. Significant Companies of Musculoskeletal Disease
Table 29. Significant Companies of Others
Table 30. Global Rare Disease Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 31. Global Rare Disease Therapeutic Sales Value by Application (2021-2026) & (US$ Million)
Table 32. Global Rare Disease Therapeutic Sales Value by Application (2027-2032) & (US$ Million)
Table 33. Global Rare Disease Therapeutic Sales Value Share by Application (2021-2026)
Table 34. Global Rare Disease Therapeutic Sales Value Share by Application (2027-2032)
Table 35. Global Rare Disease Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 36. Global Rare Disease Therapeutic Sales Value by Region (2021-2026) & (US$ Million)
Table 37. Global Rare Disease Therapeutic Sales Value Share by Region (2021-2026)
Table 38. Global Rare Disease Therapeutic Sales Value by Region (2027-2032) & (US$ Million)
Table 39. Global Rare Disease Therapeutic Sales Value Share by Region (2027-2032)
Table 40. Global Rare Disease Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 41. Global Rare Disease Therapeutic Sales Value by Country (2021-2026) & (US$ Million)
Table 42. Global Rare Disease Therapeutic Sales Value Market Share by Country (2021-2026)
Table 43. Global Rare Disease Therapeutic Sales Value by Country (2027-2032) & (US$ Million)
Table 44. Global Rare Disease Therapeutic Sales Value Market Share by Country (2027-2032)
Table 45. Bristol-Myers Squibb Company Information
Table 46. Bristol-Myers Squibb Business Overview
Table 47. Bristol-Myers Squibb Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 48. Bristol-Myers Squibb Rare Disease Therapeutic Product Portfolio
Table 49. Bristol-Myers Squibb Recent Development
Table 50. Bayer Company Information
Table 51. Bayer Business Overview
Table 52. Bayer Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Bayer Rare Disease Therapeutic Product Portfolio
Table 54. Bayer Recent Development
Table 55. AstraZeneca Company Information
Table 56. AstraZeneca Business Overview
Table 57. AstraZeneca Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 58. AstraZeneca Rare Disease Therapeutic Product Portfolio
Table 59. AstraZeneca Recent Development
Table 60. Pfizer Company Information
Table 61. Pfizer Business Overview
Table 62. Pfizer Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 63. Pfizer Rare Disease Therapeutic Product Portfolio
Table 64. Pfizer Recent Development
Table 65. Novo Nordisk A/S Company Information
Table 66. Novo Nordisk A/S Business Overview
Table 67. Novo Nordisk A/S Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Novo Nordisk A/S Rare Disease Therapeutic Product Portfolio
Table 69. Novo Nordisk A/S Recent Development
Table 70. Sanofi SA Company Information
Table 71. Sanofi SA Business Overview
Table 72. Sanofi SA Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. Sanofi SA Rare Disease Therapeutic Product Portfolio
Table 74. Sanofi SA Recent Development
Table 75. AbbVie Company Information
Table 76. AbbVie Business Overview
Table 77. AbbVie Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. AbbVie Rare Disease Therapeutic Product Portfolio
Table 79. AbbVie Recent Development
Table 80. F Hoffmann-La Roche Company Information
Table 81. F Hoffmann-La Roche Business Overview
Table 82. F Hoffmann-La Roche Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. F Hoffmann-La Roche Rare Disease Therapeutic Product Portfolio
Table 84. F Hoffmann-La Roche Recent Development
Table 85. Amgen Company Information
Table 86. Amgen Business Overview
Table 87. Amgen Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Amgen Rare Disease Therapeutic Product Portfolio
Table 89. Amgen Recent Development
Table 90. Eisai Company Information
Table 91. Eisai Business Overview
Table 92. Eisai Rare Disease Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. Eisai Rare Disease Therapeutic Product Portfolio
Table 94. Eisai Recent Development
Table 95. Novartis AG Company Information
Table 96. Novartis AG Business Overview
Table 97. Novartis AG Rare Disease Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 98. Novartis AG Rare Disease Therapeutic Product Portfolio
Table 99. Novartis AG Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Authors List of This Report
Table 102. Secondary Sources
Table 103. Primary Sources
List of Figures
Figure 1. Rare Disease Therapeutic Product Image
Figure 2. Global Rare Disease Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Rare Disease Therapeutic Market Size (2021-2032) & (US$ Million)
Figure 4. Global Rare Disease Therapeutic Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Biologics Image
Figure 8. Biosimilar Image
Figure 9. Small Molecules Image
Figure 10. Global Rare Disease Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 11. Global Rare Disease Therapeutic Sales Value Share 2021 VS 2025 VS 2032
Figure 12. Global Rare Disease Therapeutic Sales Value Share by Type (2021-2032)
Figure 13. Hematologic Disease Image
Figure 14. Cancer Image
Figure 15. Infectious Disease Image
Figure 16. Cardiovascular Disease Image
Figure 17. Metabolic Disease Image
Figure 18. Endocrine Disease Image
Figure 19. Musculoskeletal Disease Image
Figure 20. Others Image
Figure 21. Global Rare Disease Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 22. Global Rare Disease Therapeutic Sales Value Share 2021 VS 2025 VS 2032
Figure 23. Global Rare Disease Therapeutic Sales Value Share by Application (2021-2032)
Figure 24. Global Rare Disease Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 25. Global Rare Disease Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 26. North America Rare Disease Therapeutic Sales Value (2021-2032) & (US$ Million)
Figure 27. North America Rare Disease Therapeutic Sales Value Share by Country (%), 2025 VS 2032
Figure 28. Europe Rare Disease Therapeutic Sales Value (2021-2032) & (US$ Million)
Figure 29. Europe Rare Disease Therapeutic Sales Value Share by Country (%), 2025 VS 2032
Figure 30. Asia-Pacific Rare Disease Therapeutic Sales Value (2021-2032) & (US$ Million)
Figure 31. Asia-Pacific Rare Disease Therapeutic Sales Value Share by Country (%), 2025 VS 2032
Figure 32. South America Rare Disease Therapeutic Sales Value (2021-2032) & (US$ Million)
Figure 33. South America Rare Disease Therapeutic Sales Value Share by Country (%), 2025 VS 2032
Figure 34. Middle East & Africa Rare Disease Therapeutic Sales Value (2021-2032) & (US$ Million)
Figure 35. Middle East & Africa Rare Disease Therapeutic Sales Value Share by Country (%), 2025 VS 2032
Figure 36. USA Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. USA Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. USA Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Canada Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Canada Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Canada Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. Mexico Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. Mexico Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. Mexico Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. Germany Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. Germany Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. Germany Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. France Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. France Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. France Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. U.K. Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. U.K. Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. U.K. Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Italy Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Italy Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Italy Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Spain Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Spain Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Spain Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Russia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Russia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Russia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. Netherlands Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. Netherlands Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. Netherlands Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. Nordic Countries Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. Nordic Countries Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. Nordic Countries Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. China Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. China Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. China Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. Japan Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. Japan Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. Japan Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. South Korea Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. South Korea Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. South Korea Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. India Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. India Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. India Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Australia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Australia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Australia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Southeast Asia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Southeast Asia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Southeast Asia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Brazil Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Brazil Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Brazil Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Argentina Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Argentina Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Argentina Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Chile Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Chile Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Chile Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Colombia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Colombia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Colombia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Peru Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Peru Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Peru Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. Saudi Arabia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. Saudi Arabia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. Saudi Arabia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. Israel Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. Israel Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. Israel Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. UAE Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. UAE Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. UAE Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Turkey Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Turkey Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Turkey Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Iran Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 115. Iran Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 116. Iran Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 117. Egypt Rare Disease Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 118. Egypt Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 119. Egypt Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 120. Years Considered
Figure 121. Research Process
Figure 122. Key Executives Interviewed
Scope & coverage.
Types
- Biologics
- Biosimilar
- Small Molecules
Applications
- Hematologic Disease
- Cancer
- Infectious Disease
- Cardiovascular Disease
- Metabolic Disease
- Endocrine Disease
- Musculoskeletal Disease
- Others
Companies covered
- Bristol-Myers Squibb
- Bayer
- AstraZeneca
- Pfizer
- Novo Nordisk A/S
- Sanofi SA
- AbbVie
- F Hoffmann-La Roche
- Amgen
- Eisai
- Novartis AG
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Rare Disease Therapeutic Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Rare Disease Therapeutic Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Rare Disease Therapeutic Market Dynamics
- 2.1 Rare Disease Therapeutic Industry Trends
- 2.2 Rare Disease Therapeutic Industry Drivers
- 2.3 Rare Disease Therapeutic Industry Opportunities and Challenges
- 2.4 Rare Disease Therapeutic Industry Restraints
3 Rare Disease Therapeutic Market by Company
- 3.1 Global Rare Disease Therapeutic Company Revenue Ranking in 2025
- 3.2 Global Rare Disease Therapeutic Revenue by Company (2021-2026)
- 3.3 Global Rare Disease Therapeutic Company Ranking (2024-2026)
- 3.4 Global Rare Disease Therapeutic Company Manufacturing Base and Headquarters
- 3.5 Global Rare Disease Therapeutic Company Product Type and Application
- 3.6 Global Rare Disease Therapeutic Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Rare Disease Therapeutic Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Rare Disease Therapeutic Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Rare Disease Therapeutic Market by Type
- 4.1 Rare Disease Therapeutic Type Introduction
- 4.1.1 Biologics
- 4.1.2 Biosimilar
- 4.1.3 Small Molecules
- 4.2 Global Rare Disease Therapeutic Sales Value by Type
- 4.2.1 Global Rare Disease Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Rare Disease Therapeutic Sales Value by Type (2021-2032)
- 4.2.3 Global Rare Disease Therapeutic Sales Value Share by Type (2021-2032)
5 Rare Disease Therapeutic Market by Application
- 5.1 Rare Disease Therapeutic Application Introduction
- 5.1.1 Hematologic Disease
- 5.1.2 Cancer
- 5.1.3 Infectious Disease
- 5.1.4 Cardiovascular Disease
- 5.1.5 Metabolic Disease
- 5.1.6 Endocrine Disease
- 5.1.7 Musculoskeletal Disease
- 5.1.8 Others
- 5.2 Global Rare Disease Therapeutic Sales Value by Application
- 5.2.1 Global Rare Disease Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Rare Disease Therapeutic Sales Value by Application (2021-2032)
- 5.2.3 Global Rare Disease Therapeutic Sales Value Share by Application (2021-2032)
6 Rare Disease Therapeutic Regional Value Analysis
- 6.1 Global Rare Disease Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Rare Disease Therapeutic Sales Value by Region (2021-2032)
- 6.2.1 Global Rare Disease Therapeutic Sales Value by Region: 2021-2026
- 6.2.2 Global Rare Disease Therapeutic Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Rare Disease Therapeutic Sales Value (2021-2032)
- 6.3.2 North America Rare Disease Therapeutic Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Rare Disease Therapeutic Sales Value (2021-2032)
- 6.4.2 Europe Rare Disease Therapeutic Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Rare Disease Therapeutic Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Rare Disease Therapeutic Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Rare Disease Therapeutic Sales Value (2021-2032)
- 6.6.2 South America Rare Disease Therapeutic Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Rare Disease Therapeutic Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Rare Disease Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Rare Disease Therapeutic Country-level Value Analysis
- 7.1 Global Rare Disease Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Rare Disease Therapeutic Sales Value by Country (2021-2032)
- 7.2.1 Global Rare Disease Therapeutic Sales Value by Country (2021-2026)
- 7.2.2 Global Rare Disease Therapeutic Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.7.2 France Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.14.2 China Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.17.2 India Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Rare Disease Therapeutic Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Rare Disease Therapeutic Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Rare Disease Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Bristol-Myers Squibb
- 8.1.1 Bristol-Myers Squibb Company Information
- 8.1.2 Bristol-Myers Squibb Business Overview
- 8.1.3 Bristol-Myers Squibb Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.1.4 Bristol-Myers Squibb Rare Disease Therapeutic Product Portfolio
- 8.1.5 Bristol-Myers Squibb Recent Developments
- 8.2 Bayer
- 8.2.1 Bayer Company Information
- 8.2.2 Bayer Business Overview
- 8.2.3 Bayer Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.2.4 Bayer Rare Disease Therapeutic Product Portfolio
- 8.2.5 Bayer Recent Developments
- 8.3 AstraZeneca
- 8.3.1 AstraZeneca Company Information
- 8.3.2 AstraZeneca Business Overview
- 8.3.3 AstraZeneca Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.3.4 AstraZeneca Rare Disease Therapeutic Product Portfolio
- 8.3.5 AstraZeneca Recent Developments
- 8.4 Pfizer
- 8.4.1 Pfizer Company Information
- 8.4.2 Pfizer Business Overview
- 8.4.3 Pfizer Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.4.4 Pfizer Rare Disease Therapeutic Product Portfolio
- 8.4.5 Pfizer Recent Developments
- 8.5 Novo Nordisk A/S
- 8.5.1 Novo Nordisk A/S Company Information
- 8.5.2 Novo Nordisk A/S Business Overview
- 8.5.3 Novo Nordisk A/S Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.5.4 Novo Nordisk A/S Rare Disease Therapeutic Product Portfolio
- 8.5.5 Novo Nordisk A/S Recent Developments
- 8.6 Sanofi SA
- 8.6.1 Sanofi SA Company Information
- 8.6.2 Sanofi SA Business Overview
- 8.6.3 Sanofi SA Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.6.4 Sanofi SA Rare Disease Therapeutic Product Portfolio
- 8.6.5 Sanofi SA Recent Developments
- 8.7 AbbVie
- 8.7.1 AbbVie Company Information
- 8.7.2 AbbVie Business Overview
- 8.7.3 AbbVie Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.7.4 AbbVie Rare Disease Therapeutic Product Portfolio
- 8.7.5 AbbVie Recent Developments
- 8.8 F Hoffmann-La Roche
- 8.8.1 F Hoffmann-La Roche Company Information
- 8.8.2 F Hoffmann-La Roche Business Overview
- 8.8.3 F Hoffmann-La Roche Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.8.4 F Hoffmann-La Roche Rare Disease Therapeutic Product Portfolio
- 8.8.5 F Hoffmann-La Roche Recent Developments
- 8.9 Amgen
- 8.9.1 Amgen Company Information
- 8.9.2 Amgen Business Overview
- 8.9.3 Amgen Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.9.4 Amgen Rare Disease Therapeutic Product Portfolio
- 8.9.5 Amgen Recent Developments
- 8.10 Eisai
- 8.10.1 Eisai Company Information
- 8.10.2 Eisai Business Overview
- 8.10.3 Eisai Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.10.4 Eisai Rare Disease Therapeutic Product Portfolio
- 8.10.5 Eisai Recent Developments
- 8.11 Novartis AG
- 8.11.1 Novartis AG Company Information
- 8.11.2 Novartis AG Business Overview
- 8.11.3 Novartis AG Rare Disease Therapeutic Revenue and Gross Margin (2021-2026)
- 8.11.4 Novartis AG Rare Disease Therapeutic Product Portfolio
- 8.11.5 Novartis AG Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst